Promising Vaccine Targets Aggressive Triple-Negative Breast Cancer

Researchers at the Cleveland Clinic are making strides in the fight against triple-negative breast cancer (TNBC), one of the most aggressive and challenging forms of the disease to treat. A Phase 1 clinical trial has shown promising results for a novel vaccine designed to prevent recurrence and potentially even prevent the development of TNBC in high-risk individuals.

Understanding Triple-Negative Breast Cancer

Breast cancer treatment often relies on targeting specific proteins found on tumor cells, such as estrogen and progesterone receptors, and HER2. However, TNBC lacks these receptors, making it more difficult to treat with conventional therapies ¹. TNBC tends to grow and spread more quickly, and has a higher risk of recurrence, particularly in the brain, lungs, or liver ¹. Approximately 40% of women with TNBC experience a recurrence within five years of treatment ¹.

Phase 1 Trial Results

The Phase 1 clinical trial, conducted at the Cleveland Clinic, involved 35 patients. The primary goal was to assess the safety of the vaccine and observe the immune system’s response ². Participants had either previously undergone treatment and were cancer-free or were identified as being at high risk of relapse. Initial findings indicated that the vaccine stimulated an immune response, and side effects were mild, primarily limited to inflammation at the injection site ², ³.

How the Vaccine Works

The vaccine targets alpha-lactalbumin, a protein often found in breast cancer cells ⁴. By stimulating the immune system to recognize and attack cells expressing this protein, the vaccine aims to prevent cancer recurrence or development. The vaccine is an example of an adjuvant therapy ⁴.

What’s Next?

Even as the Phase 1 trial did not definitively prove the vaccine’s efficacy in preventing or curing cancer, the positive results pave the way for larger clinical trials ². Future research will focus on determining whether the vaccine can reduce the risk of cancer returning and whether it can be used to prevent the disease in high-risk individuals.

Key Takeaways

• A Phase 1 clinical trial at Cleveland Clinic shows promise for a vaccine targeting triple-negative breast cancer.
• The vaccine stimulated an immune response with mild side effects.
• Larger clinical trials are planned to assess the vaccine’s effectiveness in preventing recurrence and development of TNBC.

Sources:

1. NBC News
2. Cleveland Clinic Newsroom
3. Cleveland.com
4. ClinicalTrials.gov